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MrBACKGROUND Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular diseases that has no established therapy.
The attribute of Lp(a) that affects cardiovascular risk is not established. Low levels of Lp(a) have been associated with
type 2 diabetes (T2D).
OBJECTIVES This study investigated whether cardiovascular risk is conferred by Lp(a) molar concentration or apoli-
poprotein(a) [apo(a)] size, and whether the relationship between Lp(a) and T2D risk is causal.
METHODS This was a case-control study of 143,087 Icelanders with genetic information, including 17,715 with coronary
artery disease (CAD) and 8,734 with T2D. This study used measured and genetically imputed Lp(a) molar concentration,
kringle IV type 2 (KIV-2) repeats (which determine apo(a) size), and a splice variant in LPA associated with small apo(a)
but low Lp(a) molar concentration to disentangle the relationship between Lp(a) and cardiovascular risk. Loss-of-
function homozygotes and other subjects genetically predicted to have low Lp(a) levels were evaluated to assess the
relationship between Lp(a) and T2D.
RESULTS Lp(a) molar concentration was associated dose-dependently with CAD risk, peripheral artery disease, aortic
valve stenosis, heart failure, and lifespan. Lp(a) molar concentration fully explained the Lp(a) association with CAD, and
there was no residual association with apo(a) size. Homozygous carriers of loss-of-function mutations had little or no
Lp(a) and increased the risk of T2D.
CONCLUSIONS Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a)
concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals
with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing
T2D risk. (J Am Coll Cardiol 2019;74:2982–94) © 2019 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2019.10.019
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2983AB BR E V I A T I O N S
AND ACRONYM S
apo(a) = apolipoprotein(a)
CAD = coronary artery disease
CI = confidence interval
HbA1c = hemoglobin A1c
HDL = high density lipoprotein
KIV-2 = kringle IV type 2
LDL = low density lipoprotein
Lp(a) = lipoprotein(a)
OR = odds ratio
SNP = single nucleotide
polymorphism
T2D = type 2 diabetesL ipoprotein (a) [Lp(a)] is a risk factor for coro-nary artery disease (CAD) (1–6) and its relatedphenotypes (3,4,7–9). Mendelian randomiza-
tion studies have provided strong evidence for a
direct role of Lp(a) in their pathogenesis (3,5,8,10).
The Lp(a) particle consists of the apolipoprotein (a)
[apo(a)] glycoprotein, which is encoded by the LPA
gene and covalently bound to apolipoprotein B of
modified low-density lipoprotein (LDL) (11). CAD risk
has been associated with both Lp(a) molar concen-
tration and apo(a) size, which are inversely correlated
properties of the Lp(a) particle that are mostly
genetically determined and highly heterogeneous in
the general population. Both properties have been
suggested to be independent risk factors for CAD
(1–6,10–17).SEE PAGE 2995A common copy number polymorphism in the LPA
gene determines apo(a) size through the number of
copies of the kringle IV type 2 (KIV-2) protein domain
of apo(a). This has been estimated to account for a
large fraction of the variation in Lp(a) concentration,
in part because of altered protein folding, transport,
and secretion of larger isoforms (18). Lp(a) concen-
tration has been estimated to be >90% genetically
determined (19), and several associated variants have
been reported, including loss-of-function mutations
(20), variants associated with high Lp(a) levels and
few KIV-2 repeats (2,21), and a splice variant G4925A
that decreases Lp(a) molar concentration among in-
dividuals with few KIV-2 repeats, and therefore, small
apo(a) isoforms (22). Individuals with few KIV-2 re-
peats and low Lp(a) molar concentration and carriers
of G4925A deviate from the strong inverse relation-
ship between apo(a) isoform size and Lp(a) molar
concentration, and thus, provide an opportunity to
disentangle whether Lp(a) molar concentration,
apo(a) size, or both, affect CAD risk.
Increased risk of type 2 diabetes (T2D) has been
associated with very low Lp(a) molar concentration
and many KIV-2 repeats, but there is no correlation
with T2D risk among individuals with higher molar
concentration (23).
With Lp(a)lowering drugs being developed, it is
important to understand which attributes of Lp(a)
best capture the cardiovascular risk and the conse-
quences of Lp(a) lowering (e.g., T2D).employees of deCODE genetics, which is owned by the pharmaceutical comp
lowering drugs aimed at decreasing coronary artery disease risk. All other au
relevant to the contents of this paper to disclose.
Manuscript received December 20, 2018; revised manuscript received SepteThe aim of this study was to use Mendelian
randomization to determine whether the ef-
fect of Lp(a) on CAD risk is through molar
concentration or apo(a) isoform size and
whether very low Lp(a) molar concentration
increases T2D risk (Figure 1). We character-
ized sequence variants that affect Lp(a) molar
concentration in the Icelandic population and
tested the association of molar concentration
and KIV-2 repeats with a multitude of cardio-
vascular traits.
METHODS
The study was approved by the Data Protec-
tion Authority of Iceland and the National
Bioethics Committee of Iceland. Enrollment of par-
ticipants, the definitions of cardiovascular and car-
diometabolic phenotypes, as well as information on
blood lipid measurements, were previously described
in detail (Online Appendix) (3,24,25). The aim of the
study was to find associations between variations in
the sequence of the genome and human phenotypes.
The study started in 1996, and subjects with a broad
range of phenotypes, their relatives, and control
subjects have been recruited continuously since then.
We assigned case status, including CAD, myocardial
infarction, aortic valve stenosis, heart failure, atrial
fibrillation, peripheral artery disease, and venous
thromboembolism, based on the relevant Interna-
tional Classification of Diseases-9 and -10 codes for
discharge diagnoses (1987 to 2018) or procedure codes
(1982 to 2018), from Landspitali, The National Uni-
versity Hospital of Iceland, or from death registries
(1972 to 2009) (Online Table 1). Cases with T2D were
enrolled on the basis of 5 partially overlapping
criteria: 1) confirmed diagnosis of participants in a
long-term epidemiological study (26); 2) unrevised
hospital diagnosis of T2D; 3) self-reported T2D; 4) use
of oral diabetes medication; and 5) at least 1 measure
of hemoglobin A1c (HbA1c) >6.5%. Diagnosis of type 1
diabetes was used as an exclusion criterion.
For each casecontrol analysis, the control group
consisted of subjects free of the relevant disease.
MEASUREMENT OF Lp(a). We measured the molar
concentration of Lp(a) in serum samples using a
particle-enhanced turbidimetric immunoassay, Tina-
quant Lipoprotein (a) Gen.2 (Roche, Basel, Switzerland)any Amgen Inc. Amgen is currently developing Lp(a)
thors have reported that they have no relationships
mber 5, 2019, accepted October 6, 2019.
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pendent of Lp(a) particle size and standardized to pro-
duce Lp(a) molar concentration (nmol/l) rather than
density (mg/dl). We then imputed Lp(a) molar con-
centrations genetically into all chip-typed individuals
based on haplotype sharing over chip single nucleotide
polymorphisms (SNPs) (Online Appendix).
GENOTYPING AND IMPUTATION. Genotyping and
imputation methods, as well as the association anal-
ysis method, were previously described (24,25,27).
The sequence variants identified in subjects who
underwent whole-genome sequencing were imputed
into 151,677 Icelanders who had been genotyped with
various Illumina (San Diego, California) SNP chips and
their genotypes phased using long-range phasing
(25,28) (Online Appendix).
MEASUREMENT OF KIV-2. We used whole-genome
sequence data to measure KIV-2 (Online Appendix).
KIV-2 repeat estimates were then refined and
imputed based on haplotype sharing into all subjects
with chip genotypes.
We also genotyped KIV-2 repeats by real-time po-
lymerase chain reaction (TaqMan) in 6,640 subjects
(Online Appendix). After using haplotype sharing to
refine KIV-2 repeat measurements, the correlation
between KIV-2 repeats in parent-offspring pairs was
0.52 using the TaqMan assay (658 pairs) compared
with 0.67 when the whole-genome, sequencing-based
method (4,374 pairs) was used. The correlation be-
tween KIV-2 repeats and serum Lp(a) particle number
was also greater when we used the whole-genome
sequencing methods (R ¼ 0.54; n ¼ 6,068) than
when we used the TaqMan assaybased estimates
(R ¼ 0.45; n ¼ 6,543). Together, these results indi-
cated that the whole-genome sequencing-based and
TaqMan methods were highly correlated, but that the
whole-genome sequencing method provided a more
accurate KIV-2 repeat estimate.
ASSOCIATION ANALYSIS. Linear and logistic regres-
sion were used to test the association of quantitative
traits and case-control phenotypes, respectively, with
sequence variants. The association testing was per-
formed adjusted for sex and including sex-specific, first-
and second-order terms for year of birth.
MENDELIAN RANDOMIZATION. Mendelian random-
ization is a method of using variation in the sequence
to examine the causal effect of a nongenetic exposure
on disease (29). In the context of this paper, the idea
is to use sequence variants that affect Lp(a) molar
concentration and KIV-2 repeats that are randomized
at birth and are unaffected by Lp(a), to infer the
causal relationship between these 2 measures and
disease risk, in particular, CAD and T2D risk.ASSOCIATION WITH LIFESPAN. To test for associa-
tion with lifespan, we regressed lifespan against
allele counts at each sequence variant. We calculated
expected lifespan for subjects who were still alive and
at least 65 years old based on their sex and year of
birth. We assumed that death rates among alive
subjects were the same as among subjects born before
them. Subjects without an available death date who
were <65 years or not registered as living in Iceland
were excluded from the analysis. We did not exclude
individuals based on cause of death (e.g., accidental,
cancer, or other non-atherogenic cause of death). We
performed 2 sets of analyses, based on individuals
who lived to be at least 20 years old and those who
lived to be at least 50 years old.
Lp(a) HERITABILITY ESTIMATION. We estimated
Lp(a) heritability with 4 times the correlation be-
tween full siblings minus twice the correlation be-
tween parents and offspring (30).
RESULTS
DISTRIBUTION OF Lp(a) CONCENTRATION IN THE
POPULATION. We measured Lp(a) molar concentra-
tion in 12,137 Icelanders using an immunoturbidi-
metric method that is insensitive to the size
heterogeneity of apo(a) isoforms and is standardized
according to units of molarity (nM). Online Figure 1A
depicts the broad and skewed distribution of Lp(a)
molar concentration in Iceland, consistent with that
reported in other populations of European descent
(19), ranging from zero to approximately 600 nM (first
decile: 3.5 nM, median: 14.0 nM, and ninth decile:
122.9 nM).
SEQUENCE VARIANTS AFFECTING Lp(a) AND CAD.
Sequence variants that associate with Lp(a) molar
concentration or KIV-2 repeats are good Mendelian
randomization tools for understanding the relation-
ship between Lp(a) and cardiovascular disease risk.
We used stepwise conditional analysis at LPA, based
on variants detected by whole-genome sequencing of
15,220 Icelanders (24), to find the 3 SNPs that associ-
ated most strongly with high Lp(a) molar concentra-
tion and increased risk of CAD. One SNP was known
(2,21), 1 was a refinement of a known signal (21), and 1
SNP was novel (Online Table 2, Online Appendix).
Recently, a common splice mutation, G4925A (carrier
frequency: 22.1%), in KIV-2 repeats was found to be
associated with lower Lp(a) molar concentration and
protection against CAD among subjects with apo(a)
(22). We replicated the association of G4925A (allele
frequency in Iceland: 13.3%) with low Lp(a) molar
concentration, given the number of KIV-2 re-
peats (Figure 2).
FIGURE 1 Determination of the Relationship Between Lp(a) Molar Concentration, apo(a) Isoform Size and Cardiovascular Risk
Genetic tools Association results
Molar concentration, but not apo(a) isoform size, is the attribute of Lp(a) that affects risk of CAD
Conclusion
The CAD risk conferred by





















Lp(a) molar concentration measured in 12,137
Icelanders and genetically imputed into additional
130,950 Icelanders
• Lp(a) molar concentration is 93%-98% genetically
   determined
• KIV-2 repeats account for 52% of the variability
   of Lp(a) molar concentration
KIV-2 repeats
KIV-2 repeats estimated in 22,771 Icelanders using
whole-genome sequence data and imputed into
additional 120,316 Icelanders
• apo(a) size is determined by KIV-2 repeats
G4925A
Carriers of a common splice mutation in KIV-2
repeats, G4925A, have both small apo(a) isoforms
and low Lp(a) molar concentration
Lp(a) molar concentration associates with CAD risk
(P = 3.2×10–69) before and after accounting for
the KIV-2 repeat association (P = 3.8×10–47)
KIV-2 repeats associate with CAD risk (P = 8.1×10–24)
before but not after accounting for the Lp(a) molar
concentration association (P = 0.98)
G4925A only associates with CAD conditional on KIV-2 
repeats but not conditional on Lp(a) molar
concentration: Individuals with smaller apo(a) isoforms
but low Lp(a) molar concentration are not at increased
CAD risk
Higher risk of coronary artery disease (CAD) has been associated with higher lipoprotein(a) [Lp(a)] molar concentration and smaller apolipoprotein [apo(a)] isoforms.
These are inversely correlated properties of the Lp(a) particle. We performed Mendelian randomization to determine whether the effect of Lp(a) on CAD risk is through
molar concentration or apo(a) isoform size. We used measured and genetically imputed Lp(a) molar concentration, estimated kringle IV type 2 (KIV-2) repeats, and the
G4925A splice mutation as tools, and tested for association with CAD in 17,715 Icelandic cases with CAD and 125,739 control subjects.
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2985We identified 2 loss-of-function mutations in
Iceland with a cumulative allele frequency of
6.2% (Online Appendix). Loss-of-function variants
are useful tools for Mendelian randomization because
homozygotes and compound heterozygotes for the
loss-of-function mutations (1 in 260 individuals) al-
ways have very low Lp(a) molar concentration (me-
dian molar concentration: 2.0 nM, highest observed:
3.4 nM) (Figure 2). Thus, Lp(a) is absent or almost
absent from the blood of these individuals, validating
the loss-of-function annotation and the specificity of
the Lp(a) assay.
ASSOCIATION OF Lp(a) MOLAR CONCENTRATION
WITH CAD. We used long-range phasing (28) to infer
haplotype sharing and to determine the relativecontribution of the maternally and paternally derived
alleles to the Lp(a) molar concentration and to impute
Lp(a) molar concentration based on haplotype
sharing into a set of 130,950 Icelanders, adding to the
12,137 Icelanders with directly measured molar con-
centration. This technique captured the multitude of
sequence variants at LPA that affected Lp(a) molar
concentration (31–33) without having to enumerate or
model them explicitly. To evaluate the genetic
imputation, we removed 1,202 subjects from the
training set and found their imputation to be highly
correlated with their measured values (R2 ¼ 0.82)
(Online Figure 2). This accuracy indicated that
Lp(a) molar concentration was almost completely
determined by sequence variants at LPA. We







































































































































































































































(A) Lp(a) molar concentration by single nucleotide polymorphism (SNP) genotype and (C) allele. KIV-2 repeats by (B) SNP genotype and (D) allele. Lp(a)
molar concentration was measured in 12,137 subjects and KIV-2 repeats were measured using whole-genome sequencing in 22,771 subjects. The bottom,
middle, and top of the boxes indicate the first, second (median), and third quartile, the whiskers indicate 1.5 times the interquartile range or the minimum/
maximum values if the outlying values lie within this range. Observations outside 1.5 times the interquartile range indicated with points. Haplotype
sharing was used to deconvolute the allelic effects of the SNPs (see Methods section). Hetero ¼ heterozygous carriers; Homoz ¼ homozygous carriers;
LoF ¼ loss-of-function variants; other abbreviations as in Figure 1.
Continued on the next page
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tion to be 0.88 based on the correlation between
2,893 parent-offspring (r ¼ 0.49) and 2,943 sibling-
pairs (r ¼ 0.46), respectively.Lp(a) molar concentration associated with the risk
of CAD among 2,930 cases and 8,913 control subjects
(odds ratio [OR]: 1.15 per 50 nM; p < 0.0001) (Central






























N = 285N = 2,674N = 521N = 6,074N = 32,969N = 2,496
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2987Lp(a) and similarly associated among 14,785 cases and
116,826 control subjects with genetically imputed
Lp(a) concentrations (OR: 1.16 per 50 nM; p < 0.0001).
Furthermore, the 3 SNPs with minor alleles that
associated with increased Lp(a) molar concentration
associated with CAD with a consistent effect (18,440
cases and 133,236 control subjects; OR: 1.17 per 50 nM;
p < 0.0001). However, as expected, the association of
the SNPs was completely accounted for by the
genetically imputed Lp(a) molar concentration based
on haplotype sharing over chip SNPs that did not
include the Lp(a) increasing SNPs (p value after
adjusting for Lp(a) molar concentration ¼ 0.13). This
indicated that the genetically imputed Lp(a) concen-
tration captured all the association of the 3 SNPs in
addition to other variants.
Our data suggested that the effect of sequence
variants at LPA on CAD risk is proportionalto their effect on Lp(a) molar concentration
(Central Illustration). We predicted that 21.3%, 7.1%,
and 1.3% of Icelanders have Lp(a) over 50 nM, 150 nM,
and 250 nM, respectively, and that their CAD OR is
1.11, 1.50, and 2.01, respectively, relative to those at
the population median of 14 nM (Online Table 3).
Since these variants are all at LPA, their effect on
Lp(a) molar concentration is most likely mediated
through their effect on LPA expression.
Loss-of-function mutations in LPA were associated
with protection against CAD risk (20). When we esti-
mated the effects of the 2 loss-of-function mutations
observed in the Icelandic population jointly with the
3 Lp(a)-increasing SNPs, we did not detect an associ-
ation between the loss-of-function variants at the
locus and CAD risk (Online Table 4). This discrepancy
is explained by the fact that the previous study did
not account for the well-established variants at the
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B Type 2 Diabetes Risk by Lp(a) Molar Concentration
A Coronary Artery Disease Risk by Lp(a) Molar Concentration
Gudbjartsson, D.F. et al. J Am Coll Cardiol. 2019;74(24):2982–94.
(A) Coronary artery disease (CAD) risk and (B) type 2 diabetes risk (T2D) by lipoprotein(a) [Lp(a)] molar concentration, expressed as odds ratios
(OR) relative to the population median. The whiskers indicate 95% confidence intervals. The yellow line shows the median Lp(a) level. The
purple curve shows the cumulative distribution of Lp(a) levels (see right y-axis for scale). The blue diamonds indicate Lp(a) single nucleotide
polymorphism (SNP) genotype effects (see Figure 1). The red x indicates the CAD and T2D risk relative to the estimated risk of individuals with
the population median Lp(a) molar concentration versus genetically imputed Lp(a) molar concentration split into bins at 0, 15, 30, 60, 120,
180, and 240 nM. The black circles indicate the same, but for measured Lp(a) molar concentration. (A) Dotted blue, dashed red, and solid
black lines indicate the logistic regression fit of CAD risk as a function of Lp(a) measured by SNP effect, mean genetically imputed Lp(a) molar
concentration, and mean measure Lp(a), respectively, adjusted for sex and first- and second-order terms for year of birth.
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Our association data excluded the possibility that the
loss-of-function variants reduce the risk of CAD sub-
stantially compared with noncarriers with Lp(a)
values close to the median.
ASSOCIATION WITH CARDIOVASCULAR AND METABOLIC
PHENOTYPES AND OVERALL LIFESPAN. We tested a
combined set of measured and genetically imputed
Lp(a) molar concentrations for association with a
range of cardiovascular and metabolic phenotypes,
adjusting for year of birth and sex (Table 1, Online
Table 5). Lp(a) molar concentration was associated
with risk of various manifestations of CAD: myocar-
dial infarction, CAD burden, left main coronary artery
disease, and age of onset of CAD or myocardial
infarction (Table 1). We also replicated previous re-
ports of association of Lp(a) with aortic valve stenosis
(8), heart failure (34), ischemic stroke (driven by
large-vessel disease) (3,35), and peripheral vascular
disease (36), but not venous thromboembolism (37) or
chronic kidney disease (38).
Lp(a) molar concentration was associated with
nonhigh-density lipoprotein (non-HDL) cholesterol
levels (Table 1, Online Table 4). However, the CAD OR
of approximately 1.15 per 50 nM Lp(a) increase in
molar concentration (p < 0.0001) (Table 1, Central
Illustration) was much greater than the predicted in-
crease in risk based on the non-HDL cholesterol as-
sociation (39). Therefore, the non-HDL association of
the Lp(a) molar concentration cannot account for its
strong CAD association.
We tested the 3 Lp(a) molar concentration
increasing SNPs for association with lifespan in sub-
jects who lived to be at least 20 and 50 years old in a set
that included the relatives of subjects who were chip
genotyped. We found their lifespan to be 0.27 years
shorter per 50 nM (p < 0.0001) and 0.22 years shorter
per 50 nM (p < 0.0001), respectively (Online Table 6).
KIV-2 REPEATS, LP(A) MOLAR CONCENTRATION,
AND CAD RISK. We estimated the number of KIV-2
repeats in 22,771 Icelanders using whole-genome
sequence data and in 6,640 Icelanders using a quan-
titative polymerase chain reaction assay (TaqMan).
We measured 1,336 subjects with both methods.
Because the number of KIV-2 repeats is a property of
the individual DNA sequence, we took advantage of
haplotype sharing information derived from long-
range phasing (28) to improve genotyping accuracy
and to create phased alleles. The 2 methods gave
consistent results (R2 ¼ 0.78). We used the whole-
genome based method, which is superior to the Taq-
Man assay (Online Appendix). The distribution of
phased KIV-2 repeats had a similar multimodal dis-
tribution, as previously reported (22).Consistent with previous reports (40), we observed
a clear inverse correlation between measured Lp(a)
molar concentration and KIV-2 repeat estimates
(R ¼ 0.52; n ¼ 6,068) (Online Figure 1E and 1F). The
relationship was not simply a linear one, and the
distribution of Lp(a) molar concentration for the
fewer KIV-2 repeats was particularly broad. Some of
the variability in Lp(a) molar concentration among
subjects with few KIV-2 repeats was accounted for by
the G4925A splice variant (22).
The relationship between the 6 LPA sequence
variants [the 3 Lp(a) increasing SNPs, the 2 loss-of-
function mutations, and the splice variant G4925A]
and Lp(a) molar concentration and KIV-2 repeats at
the genotype and haplotype level are shown in Online
Figures 4 and 5.
In our set of 17,715 Icelandic cases with CAD and
125,739 control subjects with measured or genetically
imputed Lp(a) molar concentration, the association of
Lp(a) molar concentration with CAD risk was stronger
than the association of KIV-2 repeats with CAD risk
(Table 1). To compare the magnitude of effects in our
study, we compared the increase in CAD risk per 50-
nM increase of Lp(a) to the increase in CAD risk per
8.3 fewer KIV-2 repeats (both corresponded to 1.06
SDs). The estimated effect of a rise in Lp(a) molar
concentration on CAD ORs was substantially greater
than the effect of a comparable drop in the number of
KIV-2 repeats (OR: 1.16; 95% confidence interval [CI]:
1.14 to 1.18 vs. OR: 1.09; 95% CI: 1.07 to 1.11). More-
over, after accounting for the association of Lp(a)
molar concentration with CAD risk, the KIV-2 associ-
ation was no longer significant (p ¼ 0.98), whereas
the Lp(a) association remained highly significant after
accounting for KIV-2 repeats (p < 0.0001). This
pattern was consistent for all cardiovascular diseases
examined and for non-HDL and LDL cholesterol
(Table 1).
Because carriers of G4925A produce Lp(a)
(Figure 2) (22), it is not a loss-of-function mutation.
Therefore, G4925A offers a second Mendelian
randomization tool for testing whether Lp(a) molar
concentration or apo(a) size is driving the CAD asso-
ciation, because carriers have both short apo(a) iso-
forms and Lp(a) molar concentrations that are close
to that of individuals with long KIV-2 repeats
(Figures 1 and 2). We replicated the association of
G4925A with lower Lp(a) molar concentrations and
less CAD risk among subjects with few KIV-2 repeats
(Online Table 7). Similarly, G4925A was not associ-
ated with CAD risk on its own but was associated with
CAD conditional on KIV-2 repeats. Conditional on
Lp(a) molar concentration, G4925A was not associ-
ated with CAD risk at all.




Effect (95% CI) p Value
Case–control phenotypes
CAD 17,715/125,739 1.16 (1.14 to 1.18) <0.0001
Left main CAD 563/142,891 1.14 (1.06 to 1.23) 0.00031
Coronary artery bypass grafting 3,347/140,107 1.27 (1.24 to 1.31) <0.0001
Myocardial infarction 9,575/133,879 1.18 (1.16 to 1.21) <0.0001
Aortic valve stenosis 1,608/141,846 1.17 (1.12 to 1.22) <0.0001
Heart failure 8,494/134,960 1.05 (1.02 to 1.07) <0.0001
Atrial fibrillation 9,468/133,986 1.01 (0.99 to 1.03) 0.21
Ischemic stroke 4,209/139,245 1.03 (1.00 to 1.07) 0.023
Cardioembolic stroke 1,074/142,380 1.02 (0.96 to 1.08) 0.50
Small-vessel stroke 510/142,944 0.98 (0.90 to 1.06) 0.59
Large-vessel stroke 405/143,049 1.11 (1.01 to 1.21) 0.023
Peripheral artery disease 2,465/140,989 1.16 (1.12 to 1.21) <0.0001
Venous thromboembolism 2,594/140,860 1.00 (0.96 to 1.04) 0.98
Chronic kidney disease 11,664 131,790 1.02 (1.00 to 1.04) 0.036
Quantitative phenotypes
Coronary arteries 1 to 4 >50% stenosis* 7,347 0.06 (0.04 to 0.07) <0.0001
CAD age at onset* 17,715 0.22 (0.31 to 0.12) <0.0001
Age at myocardial infarction* 9,575 0.14 (0.26 to 0.02) 0.026
Total cholesterol† 94,920 0.06 (0.05 to 0.06) <0.0001
HDL cholesterol† 88,644 0.01 (0.00 to 0.01) 0.012
LDL cholesterol† 82,854 0.06 (0.05 to 0.07) <0.0001
Non–HDL cholesterol† 88,455 0.05 (0.04 to 0.06) <0.0001
Triglycerides‡ 77,186 1 (2 to 1) <0.0001
Fasting glucose† 67,274 0.01 (0.01 to 0.00) 0.017
HbA1c§ 44,627 0.01 (0.01 to 0.00) 0.049
Effects for diseases are given in odds ratios (ORs). Effects are scaled to 50-nM increase in lipoprotein(a) [Lp(a)] concentration, and 95% confidence intervals (CIs) are given.
Kringle IV type 2 (KIV-2) repeat effects have been inverted and scaled to correspond to 50 nM of a Lp(a) increase. Association testing for case-control phenotypes was
performed with logistic regression and with linear regression for quantitative phenotypes, both adjusting for sex and year of birth. *Effects are SD. †Effects are in millimoles per
liter. ‡Effects are in percentages. §Effects are in percentages of glycated hemoglobin.
CAD ¼ coronary artery disease; HbA1c ¼ hemoglobin A1c; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
Continued on the next page
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TRIGLYCERIDES. Interestingly, the number of KIV-2
repeats associated negatively with HDL cholesterol
and positively with triglycerides, even conditional on
Lp(a) molar concentration (Table 1). Lp(a) concentra-
tion had weaker associations in the opposite direction
with these traits (41), which were no longer signifi-
cant after accounting for KIV-2 repeats. Because the
LPA splice site variant G4925A affected the composi-
tion of apo(a) isoforms beyond what was predicted by
KIV-2 (22), the variant should associate with HDL
cholesterol and triglycerides given the KIV-2 repeat
number. We found an association with HDL cholesterol
(p ¼ 0.00052) and triglycerides (p ¼ 0.0010).
ASSOCIATION WITH T2D. The 10% of subjects with
very low Lp(a) molar concentration (<3.5 nM) were
reported to be at greater risk of T2D (23). Wereplicated this association (OR: 1.44; p < 0.0001)
(Central Illustration, Online Figure 6, Table 2). How-
ever, T2D risk was independent of molar concentra-
tion in subjects with levels above the median. The
top quintile of repeats was used as a tool in Men-
delian randomization to show that the association
between very low Lp(a) concentration and increased
T2D risk was causal (42). We did not replicate this
association (Table 2). Sequence variants associated
with more KIV-2 repeats, but not with Lp(a) levels,
were associated with increased risk of T2D in a small
sample of 8,411 Danes (43). The interpretation was
that many KIV-2 repeats were associated causally
with increased risk of T2D but not low Lp(a) molar
concentrations. However, we did not replicate this
association (Online Table 8).
Loss-of-function homozygotes and subjects with





KIV-2 Adjusted for Lp(a)
Molar Concentration
Effect (95% CI) p Value Effect (95% CI) p Value Effect (95% CI) p Value
1.09 (1.07 to 1.11) <0.0001 1.16 (1.13 to 1.18) <0.0001 1.00 (0.98 to 1.02) 0.98
1.07 (0.99 to 1.15) 0.11 1.16 (1.06 to 1.26) 0.0011 0.97 (0.88 to 1.07) 0.56
1.20 (1.16 to 1.24) <0.0001 1.25 (1.21 to 1.30) <0.0001 1.03 (0.99 to 1.08) 0.13
1.11 (1.09 to 1.14) <0.0001 1.18 (1.15 to 1.21) <0.0001 1.00 (0.98 to 1.03) 0.79
1.09 (1.04 to 1.14) 0.00028 1.18 (1.12 to 1.25) <0.0001 0.98 (0.93 to 1.04) 0.47
1.03 (1.01 to 1.06) 0.0046 1.04 (1.01 to 1.07) 0.0048 1.01 (0.98 to 1.04) 0.46
1.02 (1.00 to 1.05) 0.025 1.00 (.97 to 1.03) 1.00 1.02 (1.00 to 1.05) 0.065
1.01 (0.98 to 1.04) 0.37 1.04 (1.00 to 1.08) 0.033 0.99 (.096 to 1.03) 0.64
1.02 (0.96 to 1.08) 0.57 1.02 (.95 to 1.09) 0.66 1.01 (0.94 to 1.08) 0.82
0.98 (0.90 to 1.06) 0.59 0.99 (0.89 to 1.09) 0.78 0.99 (0.89 to 1.09) 0.78
1.05 (0.96 to 1.15) 0.27 1.12 (1.00 to 1.24) 0.044 0.99 (0.88 to 1.10) 0.79
1.11 (1.07 to 1.15) <0.0001 1.16 (1.11 to 1.21) <0.0001 1.01 (0.96 to 1.06) 0.73
1.03 (0.99 to 1.07) 0.12 0.98 (0.93 to 1.02) 0.27 1.04 (1.00 to 1.09) 0.055
1.01 (0.99 to 1.03) 0.60 1.03 (1.00 to 1.05) 0.029 0.99 (0.97 to 1.01) 0.42
0.04 (0.03 to 0.06) <0.0001 0.05 (0.03 to 0.07) <0.0001 0.01 (0.01 to 0.02) 0.25
0.12 (0.21 to 0.03) 0.012 0.23 (0.35 to 0.11) <0.0001 0.03 (0.03 to 0.08) 0.34
0.09 (0.20 to 0.02) 0.12 0.14 (0.28 to 0.01 0.061 0.00 (0.00 to 0.00) 0.50
0.03 (0.03 to 0.04) <0.0001 0.06 (0.05 to 0.06) <0.0001 0.00 (0.00 to 0.00) 0.47
0.02 (0.01 to 0.03) <0.0001 0.01 (0.01 to 0.00) 0.066 0.02 (0.02 to 0.03) <0.0001
0.04 (0.03 to 0.04) <0.0001 0.06 (0.05 to 0.07) <0.0001 0.00 (0.00 to 0.00) 0.34
0.02 (0.02 to 0.03) <0.0001 0.05 (0.05 to 0.06) <0.0001 0.01 (0.01 to 0.00) 0.025
3 (3 to 2) <0.0001 0 (0 to 0) 0.41 3 (3 to 2) <0.0001
0.00 (0.01 to 0.00) 0.097 0.01 (0.01 to 0.00) 0.047 0.00 (0.00 to 0.00) 0.45
0.00 (0.00 to 0.00) 0.39 0.01 (0.01 to 0.00) 0.035 0.00 (0.00 to 0.01) 0.21
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2991concentration (<3.5 nM) provide additional Mende-
lian randomization tools to explore the causality of
the association between very low Lp(a) molar con-
centration and T2D (Table 2). The loss-of-function
homozygosity associated with increased risk of T2D
(OR: 1.45; p ¼ 0.022) as did very low genetically
imputed Lp(a) molar concentrations (OR: 1.16;
p ¼ 0.0012), which demonstrated a causal link be-
tween very low Lp(a) levels and T2D risk.TABLE 2 Association Between Low Lp(a) Molar Concentration and T2
Cov% No. T2D
KIV-2 top 20% vs. remainder 20 8,734
LoF homozygous 0.41 8,734
Measured Lp(a) <3.5 nM 10.1 1,548
Measured Lp(a) <3.5 nM – not LoF homozygous 9.8 1,537
Imputed Lp(a) <3.5 nM* 7.4 7,186
Imputed Lp(a) <3.5 nM* – not LoF homozygous 7.0 7,149
*Does not overlap with individuals with measured Lp(a) molar concentration. The fractio
controls, ORs, their 95% CIs, and p values are displayed. Association was performed wi
LoF ¼ loss of function; T2D ¼ type 2 diabetes; other abbreviations as in Table 1.We investigated whether the association with T2D
was driven by linkage disequilibrium with known T2D
variants. A single SNP associated with T2D in the re-
gion around LPA (rs622217; published OR: 1.05) (44).
This variant is only in weak linkage disequilibrium
with the LPA loss-of-function variants (r2 ¼ 0.024)
and conditioning on its effect did not affect the as-
sociation of LPA loss-of-function homozygosity with






Covariate OR (95% CI) p Value
134,720 6.1 6.1 1.01 (0.95–1.06) 0.85
134,720 8.2 6.1 1.45 (1.05–1.99) 0.022
10,295 16.4 12.7 1.44 (1.21–1.71) <0.0001
10,253 16.2 12.7 1.42 (1.19–1.69) 0.00010
124,425 6.3 5.4 1.17 (1.07–1.28) 0.00051
123,931 6.3 5.4 1.16 (1.06–1.27) 0.0012
n of individuals with the covariate (Cov%) is shown, along with the number of cases, the number of
th logistic regression, adjusting for sex and year of birth.
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of-function homozygosity nor measured very low
Lp(a) molar concentration associated with body
mass index (p > 0.26), which demonstrated that the
association with T2D is not driven by an association
with body mass index.
DISCUSSION
Through large-scale estimation of Lp(a) molar con-
centration, KIV-2 repeats, and genotyping, we
showed that the atherogenic effect of Lp(a) is
conferred through the molar concentration and not
apo(a) size, in contradiction to some of the existing
literature (Figure 1). In particular, subjects with few
KIV-2 repeats, and therefore, small apo(a) isoforms
but low Lp(a) molar concentration were not at
increased CAD risk. Similarly, carriers of the splice
variant G4925A had short apo(a) isoforms but low
Lp(a) molar concentration and were not at increased
risk of CAD. This suggested that risk prediction
based on Lp(a) should only depend on molar con-
centration and that treatment of Lp(a) should focus
on lowering the molar concentration in subjects with
high Lp(a) levels, regardless of the apo(a) size dis-
tribution. These findings were in line with analysis
from the Bruneck study (45) (n ¼ 826), which
showed that Lp(a) levels improved cardiovascular
disease risk prediction with no added value of apo(a)
size.
We consistently found the same pattern for all
cardiovascular diseases examined and for non-HDL
and LDL cholesterol. Furthermore, because Lp(a)
molar concentration was almost fully determined by
sequence variants at LPA and was not substantially
influenced by other factors (e.g., age, sex, other
inherited factors, or the environment), the measured
Lp(a) molar concentration captured most of the CAD
risk associated with Lp(a). Consequently, both risk
assessment and a therapeutic strategy can be based
on measured Lp(a) molar concentration, regardless of
the size of the apo(a) isoform and sequence variants
that affect Lp(a) concentration.
Interestingly, apo(a) size appears to affect HDL
cholesterol and triglyceride levels, while Lp(a) molar
concentration does not. Neither HDL cholesterol nor
triglyceride levels have been proven to have a causal
effect on cardiovascular disease (39). Although these
measures associate with CAD risk, their association is
explained by their correlation with non-HDL choles-
terol (39). This finding suggests that apo(a) size mayhave a biological function, although not conferring
cardiovascular risk.
We replicated the association between very low
measured Lp(a) molar concentration and increased
T2D risk. In addition, we performed Mendelian
randomization studies using loss-of-function variants
and genetic imputation to show that this association
is likely to be causal. We did not replicate the results
of a previous study that used the top quintile of KIV-2
repeats as a Mendelian randomization tool (42),
and we did not replicate a recent finding that sug-
gested that the T2D risk association with Lp(a) was
due to KIV-2 repeats rather than Lp(a) molar con-
centrations (43).
STUDY LIMITATIONS. Our study was limited to the
Icelandic population. Follow-up in more European
and in non-European populations is important.
Imputation of genotypes and phenotypic prediction
based on haplotype sharing was always inferior to
direct measurement, although the imputations were
shown to be sufficiently accurate. The measurement
of Lp(a) molar concentration is not standardized in
clinical practice; therefore, absolute thresholds and
effect estimates may depend on the measurement
platform (15). We noted that the median Lp(a) con-
centrations we observed were low relative to most
other reports on Europeans, which is probably
because of measurement heterogeneity rather than
true differences between the populations.
CONCLUSIONS
Molar concentration was the attribute of Lp(a) that
affected risk of CAD and other cardiovascular dis-
eases. The association between the Lp(a) molar con-
centration and risk of CAD was dose-dependent and
increased from an OR of 1.11 for those with Lp(a)
levels at the 79th percentile (50 nM) to an OR of 2.01
for those with Lp(a) levels at the 99th percentile (250
nM), compared with those who had the Lp(a) popu-
lation median level (14 nM). Lowering the Lp(a) levels
of subjects with concentration above the 79th
percentile (50 nM) to the population median of 14 nM
could substantially reduce risk of cardiovascular dis-
ease and is not predicted to increase risk of T2D.
ADDRESS FOR CORRESPONDENCE: Dr. Kari Ste-
fansson, Sturlugata 8, 101 Reykjavik, Iceland. E-mail:
kari.stefansson@decode.is. Twitter: @decodegenetics.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Based on
Mendelian randomization in an Icelandic population, Lp(a)
molar concentrations fully explained the association of
Lp(a) with CAD, and there was no residual association
with apo(a) particle size. Individuals with very low Lp(a)
levels are at increased risk of developing T2D, indicating a
causal link with absence of Lp(a).
TRANSLATIONAL OUTLOOK: Further studies are
needed to verify the generalizability of these observa-
tions to other populations and to develop risk assessment
and therapeutic strategies based on Lp(a) molar concen-
tration rather than apo(a) isoform or sequence variants.
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